title: [Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
abstract: Lung cancer is a leading cause of malignancy-related death worldwide. Recently, therapeutic strategies for lung cancer have dramatically progressed, and attempts have been made to standardize the therapy for lung cancer. Because the disease prevalence and the susceptibility to the drugs differ with the circumstances, such as lifestyle, and genetic background, and ethnicity, the standard therapeutic strategies for lung cancer may differ with the individual country or region. Actually, the EGFR tyrosine kinase inhibitor, gefitinib, is well known to be significantly effective for oriental people, including Japanese, female, adenocarcinoma and never-smoker, suggesting an inherited difference. Here we describe not only the standard therapeutic strategies but also the difference in therapeutic strategies for lung cancer between Europe/United States and Japan.
authors.affiliation: Dept. of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima. Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Hanibuchi
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
authors.forename: Hideki
authors.initials: H
authors.lastname: Tomimoto
authors.forename: Saburo
authors.initials: S
authors.lastname: Sone
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000601:surgery / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005060:Europe; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000601:surgery / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage; D014481:United States; D014498:Uracil / Q000008:administration & dosage
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D005641:Tegafur; D014498:Uracil; D002945:Cisplatin; D000077156:Gefitinib